...
首页> 外文期刊>Vaccine >DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates
【24h】

DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates

机译:表达糖蛋白复合物II抗原gM和gN的DNA疫苗引发针对多种人类巨细胞病毒(HCMV)分离株的中和抗体

获取原文
获取原文并翻译 | 示例
           

摘要

Human cytomegalovirus (HCMV) glycoprotein complex II (gcII) consists of two glycoproteins, gM and gN. Although gcII specific IgG purified from HCMV positive patient sera can neutralize HCMV, there has been no report describing the generation of virus-neutralizing antibodies by immunization with individual recombinant gM or gN antigens. In the current study, gM and gN antigens were expressed by the mammalian expression vector pJW4303 and used as DNA vaccines to determine the immunogenicity of these proteins. Sera from mice or rabbits immunized with individual or combinations of gM and gN DNA vaccines contained gM and gN specific antibodies as confirmed by ELISA and Western blot analyses. The combined gM and gN antigens induced the strongest antibody responses that recognized both gM and gcII complex while gM DNA vaccine alone could only elicit antibody specific for gM antigen. When given alone, the gN DNA vaccine did not induce detectable gcII specific antibody even though in vitro gN expression was confirmed by the formation of gM/gN complex in FSK cells using a gN-specific monoclonal antibody 14-16A. The neutralizing antibody titer of anti-gM/gN sera (1:128) was higher than that of anti-gM sera (1:32) against the autologous virus, HCMV AD169. Heterologous HCMV strains including Towne and Davis could also be neutralized by the anti-gM/gN antisera. Our data supported the rationale for the use of the HCMV gM/gN protein complex as protective antigens for subunit based HCMV vaccine development. DNA vaccination is an effective approach to express the gM/gN antigen complex in vivo without the need to express and purify these highly insoluble and structurally complicated antigens.
机译:人巨细胞病毒(HCMV)糖蛋白复合物II(gcII)由两种糖蛋白gM和gN组成。尽管从HCMV阳性患者血清中纯化的gcII特异性IgG可以中和HCMV,但尚未有报道描述通过用单个重组gM或gN抗原免疫来产生病毒中和抗体。在当前的研究中,gM和gN抗原由哺乳动物表达载体pJW4303表达,并用作DNA疫苗以确定这些蛋白质的免疫原性。如通过ELISA和Western印迹分析所证实的,用gM和gN DNA疫苗的个体或组合免疫的小鼠或兔子的血清含有gM和gN特异性抗体。结合的gM和gN抗原诱导了最强的抗体反应,可以识别gM和gcII复合物,而单独的gM DNA疫苗只能引起对gM抗原具有特异性的抗体。当单独使用gN DNA疫苗时,即使通过使用gN特异性单克隆抗体14-16A在FSK细胞中形成gM / gN复合物证实了体外gN表达,gN DNA疫苗也不诱导可检测的gcII特异性抗体。抗gM / gN血清(1:128)的中和抗体滴度高于针对自体病毒HCMV AD169的抗gM血清(1:32)的滴度。包括Towne和Davis在内的异源HCMV菌株也可以被抗gM / gN抗血清中和。我们的数据支持将HCMV gM / gN蛋白复合物用作基于亚单位的HCMV疫苗开发的保护性抗原的基本原理。 DNA疫苗接种是在体内表达gM / gN抗原复合物的有效方法,无需表达和纯化这些高度不溶和结构复杂的抗原。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号